Cargando…

Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial

OBJECTIVE: Kikyo-to (KKT) is a fixed combination of glycyrrhiza root and platycodon root extracts. It is an herbal medicine traditionally used in Japan for relieving sore throat associated with acute upper respiratory tract infection (URTI). No controlled studies have yet demonstrated its effect, ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishimaru, Naoto, Kinami, Saori, Shimokawa, Toshio, Kanzawa, Yohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761347/
https://www.ncbi.nlm.nih.gov/pubmed/31178508
http://dx.doi.org/10.2169/internalmedicine.2748-19
_version_ 1783454011241791488
author Ishimaru, Naoto
Kinami, Saori
Shimokawa, Toshio
Kanzawa, Yohei
author_facet Ishimaru, Naoto
Kinami, Saori
Shimokawa, Toshio
Kanzawa, Yohei
author_sort Ishimaru, Naoto
collection PubMed
description OBJECTIVE: Kikyo-to (KKT) is a fixed combination of glycyrrhiza root and platycodon root extracts. It is an herbal medicine traditionally used in Japan for relieving sore throat associated with acute upper respiratory tract infection (URTI). No controlled studies have yet demonstrated its effect, however. We investigated the efficacy of KKT on sore throat associated with acute URTI. METHODS: Patients with sore throat who were diagnosed with URTI at the General Medicine Department Office, Akashi Medical Center Hospital, between December 2017 and May 2018 were enrolled. Participants were randomly assigned to two groups at a 1:1 ratio, with stratification by age and sore throat score on a Visual Analogue Scale (VAS), to receive 2.5 g of either KKT or a placebo. Participants and investigators were blinded to group allocation. The primary outcome was the change in sore throat score on VAS 10 minutes after KKT administration. Secondary outcomes were the impact of the sore throat on daily life (none, mild, moderate, and severe) at 10 minutes after administration. RESULTS: Thirty-five participants were assigned to each group (n=70, total). The difference in the mean change of sore throat score according to VAS within 10 minutes between the two groups was not statistically significant (KKT 14.40 vs. placebo 17.00; p=0.39). The proportion of patients with a moderate or greater impact of their sore throat on their daily life was also not significantly different between the groups (KKT 22.9% vs. placebo 40.0%; p=0.20). Patients reported no side effects. CONCLUSION: KKT did not significantly relieve sore throat associated with acute URTI compared with placebo.
format Online
Article
Text
id pubmed-6761347
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-67613472019-09-27 Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial Ishimaru, Naoto Kinami, Saori Shimokawa, Toshio Kanzawa, Yohei Intern Med Original Article OBJECTIVE: Kikyo-to (KKT) is a fixed combination of glycyrrhiza root and platycodon root extracts. It is an herbal medicine traditionally used in Japan for relieving sore throat associated with acute upper respiratory tract infection (URTI). No controlled studies have yet demonstrated its effect, however. We investigated the efficacy of KKT on sore throat associated with acute URTI. METHODS: Patients with sore throat who were diagnosed with URTI at the General Medicine Department Office, Akashi Medical Center Hospital, between December 2017 and May 2018 were enrolled. Participants were randomly assigned to two groups at a 1:1 ratio, with stratification by age and sore throat score on a Visual Analogue Scale (VAS), to receive 2.5 g of either KKT or a placebo. Participants and investigators were blinded to group allocation. The primary outcome was the change in sore throat score on VAS 10 minutes after KKT administration. Secondary outcomes were the impact of the sore throat on daily life (none, mild, moderate, and severe) at 10 minutes after administration. RESULTS: Thirty-five participants were assigned to each group (n=70, total). The difference in the mean change of sore throat score according to VAS within 10 minutes between the two groups was not statistically significant (KKT 14.40 vs. placebo 17.00; p=0.39). The proportion of patients with a moderate or greater impact of their sore throat on their daily life was also not significantly different between the groups (KKT 22.9% vs. placebo 40.0%; p=0.20). Patients reported no side effects. CONCLUSION: KKT did not significantly relieve sore throat associated with acute URTI compared with placebo. The Japanese Society of Internal Medicine 2019-06-07 2019-09-01 /pmc/articles/PMC6761347/ /pubmed/31178508 http://dx.doi.org/10.2169/internalmedicine.2748-19 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ishimaru, Naoto
Kinami, Saori
Shimokawa, Toshio
Kanzawa, Yohei
Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title_full Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title_fullStr Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title_full_unstemmed Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title_short Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial
title_sort kikyo-to vs. placebo on sore throat associated with acute upper respiratory tract infection: a randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761347/
https://www.ncbi.nlm.nih.gov/pubmed/31178508
http://dx.doi.org/10.2169/internalmedicine.2748-19
work_keys_str_mv AT ishimarunaoto kikyotovsplaceboonsorethroatassociatedwithacuteupperrespiratorytractinfectionarandomizedcontrolledtrial
AT kinamisaori kikyotovsplaceboonsorethroatassociatedwithacuteupperrespiratorytractinfectionarandomizedcontrolledtrial
AT shimokawatoshio kikyotovsplaceboonsorethroatassociatedwithacuteupperrespiratorytractinfectionarandomizedcontrolledtrial
AT kanzawayohei kikyotovsplaceboonsorethroatassociatedwithacuteupperrespiratorytractinfectionarandomizedcontrolledtrial